View Future GrowthBarito Pacific 과거 순이익 실적과거 기준 점검 4/6Barito Pacific은 연평균 48.8%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 4.4% 감소했습니다. 매출은 연평균 13.4%의 비율로 증가했습니다. Barito Pacific의 자기자본이익률은 26.7%이고 순이익률은 6.4%입니다.핵심 정보48.75%순이익 성장률49.04%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률13.40%자기자본이익률26.72%순이익률6.42%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.Reported Earnings • May 03First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 30Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022)Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • May 20PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026.공시 • Feb 04PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares.PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026.Board Change • Dec 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • May 14PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025. Location: jakarta Indonesia공시 • Apr 25PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion.PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion on April 21, 2025. A cash consideration of IDR 90 billion will be paid by PT Buana Primatama Niaga and PT Chandra Daya Investasi for 20,390 shares. The composition of BIP's share ownership after the share acquisition has changed. CDI is now the majority shareholder in BIP, namely 20,399 shares worth IDR 20.39 billion (99.99%). The remaining 1 share (1%) or worth IDR 1 million is owned by BPN. In order to support this transformation, BRPT and GI intend to transfer all share ownership in BIP to the CAP Group and its affiliates, namely BIP and BPN, so that the logistics business line can be more focused on being developed by the CAP Group. The object of this affiliate transaction is all shares owned by BRPT and all shares owned by GI in BIP with a total of 20,400 shares or representing 100% of all shares issued in BIP. The value of this transaction is recorded at IDR 90 billion. Kantor Jasa Penilai Publik Syarif, Endang & Partners acted as fairness opinion provider for PT Barito Pacific Tbk.Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.공시 • May 12PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024.Buy Or Sell Opportunity • May 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.3% to €0.049. The fair value is estimated to be €0.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 78%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 1,155% in the next year.Reported Earnings • May 03First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 28% to €0.048. The fair value is estimated to be €0.039, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 61%. Revenue is forecast to grow by 4.5% in 2 years. Earnings are forecast to grow by 349% in the next 2 years.Reported Earnings • Mar 30Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022)Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Mar 08Now 24% overvaluedOver the last 90 days, the stock has fallen 46% to €0.051. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.Buy Or Sell Opportunity • Feb 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to €0.05. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.Buy Or Sell Opportunity • Feb 07Now 34% overvalued after recent price riseOver the last 90 days, the stock has risen 34% to €0.067. The fair value is estimated to be €0.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Jun 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: US$650.7m (down 20% from 1Q 2022). Net income: US$23.3m (up 149% from 1Q 2022). Profit margin: 3.6% (up from 1.1% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 02Second quarter 2022 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2021)Second quarter 2022 results: EPS: US$0 (down from US$0.001 in 2Q 2021). Revenue: US$804.3m (down 3.0% from 2Q 2021). Net loss: US$509.0k (down 101% from profit in 2Q 2021). Revenue is forecast to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). President Commissioner Prajogo Pangestu is the most experienced director on the board, commencing their role in 1993. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Apr 06Full year 2021 earnings released: EPS: US$0.001 (vs US$0 in FY 2020)Full year 2021 results: EPS: US$0.001 (up from US$0 in FY 2020). Revenue: US$3.16b (up 35% from FY 2020). Net income: US$109.1m (up 201% from FY 2020). Profit margin: 3.5% (up from 1.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.1%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Jul 01PT Barito Pacific to Be Deleted from Other OTCPT Barito Pacific TBK Ordinary Shares will be deleted from Other OTC effective July 01, 2021. The deletion is due to Inactive Security.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$2.33b (down 2.8% from FY 2019). Net income: US$36.3m (down 18% from FY 2019). Profit margin: 1.6% (down from 1.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.매출 및 비용 세부 내역Barito Pacific가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:OB8 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 257,631490422030 Sep 256,274612250030 Jun 254,456562199031 Mar 252,54264178031 Dec 242,38756169030 Sep 242,32517188030 Jun 242,54530205031 Mar 242,72812208031 Dec 232,76026207030 Sep 232,69726199030 Jun 232,71823176031 Mar 232,79916182031 Dec 222,9622177030 Sep 223,21920175030 Jun 223,21816178031 Mar 223,24373166031 Dec 213,156109161030 Sep 212,982123171030 Jun 212,786158168031 Mar 212,45090162031 Dec 202,33442158030 Sep 202,29651145030 Jun 202,20419150031 Mar 202,33436151031 Dec 192,40244154030 Sep 192,49028147030 Jun 192,82750141031 Mar 192,92860140031 Dec 183,07688143030 Sep 183,108109143030 Jun 183,031128143031 Mar 183,043142149031 Dec 172,852159134030 Sep 172,642162119030 Jun 172,438163103031 Mar 172,23117088001 Jan 172,10616189030 Sep 161,6658675030 Jun 161,4914672031 Mar 161,409574031 Dec 151,406-575030 Sep 151,683280030 Jun 151,984-5840양질의 수익: OB8는 $1.9B 규모의 큰 일회성 이익이 있어 31st December, 2025까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: OB8의 현재 순 이익률 (6.4%)은 지난해 (2.4%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: OB8의 수익은 지난 5년 동안 연평균 48.8%로 크게 증가했습니다.성장 가속화: 지난 1년간 OB8 의 수익 증가율(767.2%)은 연간 평균(48.8%)을 초과합니다.수익 대 산업: OB8의 지난 1년 수익 증가율(767.2%)은 Chemicals 업계의 -13.5%를 상회했습니다.자기자본이익률높은 ROE: OB8의 자본 수익률(26.72%)은 높음이지만 높은 부채 수준으로 인해 왜곡되어 있습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 19:05종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PT Barito Pacific Tbk는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Justian Rama LiusudarsoCitigroup IncArnanto JanuriJ.P. MorganRichardo WalujoMacquarie Research5명의 분석가 더 보기
Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 03First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 30Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022)Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • May 20PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026.
공시 • Feb 04PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares.PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026.
Board Change • Dec 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • May 14PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025. Location: jakarta Indonesia
공시 • Apr 25PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion.PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion on April 21, 2025. A cash consideration of IDR 90 billion will be paid by PT Buana Primatama Niaga and PT Chandra Daya Investasi for 20,390 shares. The composition of BIP's share ownership after the share acquisition has changed. CDI is now the majority shareholder in BIP, namely 20,399 shares worth IDR 20.39 billion (99.99%). The remaining 1 share (1%) or worth IDR 1 million is owned by BPN. In order to support this transformation, BRPT and GI intend to transfer all share ownership in BIP to the CAP Group and its affiliates, namely BIP and BPN, so that the logistics business line can be more focused on being developed by the CAP Group. The object of this affiliate transaction is all shares owned by BRPT and all shares owned by GI in BIP with a total of 20,400 shares or representing 100% of all shares issued in BIP. The value of this transaction is recorded at IDR 90 billion. Kantor Jasa Penilai Publik Syarif, Endang & Partners acted as fairness opinion provider for PT Barito Pacific Tbk.
Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
공시 • May 12PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024.
Buy Or Sell Opportunity • May 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.3% to €0.049. The fair value is estimated to be €0.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 78%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 1,155% in the next year.
Reported Earnings • May 03First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 28% to €0.048. The fair value is estimated to be €0.039, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 61%. Revenue is forecast to grow by 4.5% in 2 years. Earnings are forecast to grow by 349% in the next 2 years.
Reported Earnings • Mar 30Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022)Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Mar 08Now 24% overvaluedOver the last 90 days, the stock has fallen 46% to €0.051. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.
Buy Or Sell Opportunity • Feb 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to €0.05. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.
Buy Or Sell Opportunity • Feb 07Now 34% overvalued after recent price riseOver the last 90 days, the stock has risen 34% to €0.067. The fair value is estimated to be €0.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jun 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: US$650.7m (down 20% from 1Q 2022). Net income: US$23.3m (up 149% from 1Q 2022). Profit margin: 3.6% (up from 1.1% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 02Second quarter 2022 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2021)Second quarter 2022 results: EPS: US$0 (down from US$0.001 in 2Q 2021). Revenue: US$804.3m (down 3.0% from 2Q 2021). Net loss: US$509.0k (down 101% from profit in 2Q 2021). Revenue is forecast to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). President Commissioner Prajogo Pangestu is the most experienced director on the board, commencing their role in 1993. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Apr 06Full year 2021 earnings released: EPS: US$0.001 (vs US$0 in FY 2020)Full year 2021 results: EPS: US$0.001 (up from US$0 in FY 2020). Revenue: US$3.16b (up 35% from FY 2020). Net income: US$109.1m (up 201% from FY 2020). Profit margin: 3.5% (up from 1.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.1%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Jul 01PT Barito Pacific to Be Deleted from Other OTCPT Barito Pacific TBK Ordinary Shares will be deleted from Other OTC effective July 01, 2021. The deletion is due to Inactive Security.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$2.33b (down 2.8% from FY 2019). Net income: US$36.3m (down 18% from FY 2019). Profit margin: 1.6% (down from 1.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.